News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Vitrolife: Interim Report January - July 2010
July 15, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
STOCKHOLM--(BUSINESS WIRE)--Vitrolife (STO:VITR): Period January – June - Growth in local currency was 14 percent. Sales amounted to SEK 149 (142) million, corresponding to an increase of 5 percent in SEK.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Earnings
AstraZeneca Teases ‘Very Competitive’ Weight-Loss Pill—But Stays Mum on Details
February 10, 2026
·
2 min read
·
Tristan Manalac
Recruiting
Facing Talent Crunch, Radiopharma Field Casts a Wide Net
February 10, 2026
·
4 min read
·
Nick Paul Taylor
Mergers & acquisitions
Eli Lilly Enters CAR T Realm With $2.4B Orna Buy, Starting With Autoimmune
February 9, 2026
·
2 min read
·
Dan Samorodnitsky
Layoff Tracker
Delayed Notice Reveals 141 More Layoffs From Genentech in 2025
February 9, 2026
·
52 min read
·
BioSpace Editorial Staff
